Beginning this month, Louisiana has been able to treat hundreds of patients who were waiting to receive a cure for hepatitis C thanks to an innovative “modified subscription model” in which the state pays a fixed amount to a manufacturer for a drug, up to a spending cap, and in return gets unlimited access to the therapy for Medicaid beneficiaries. But the road to get there was long and difficult, according to Rebekah Gee, M.D., secretary of the Louisiana Dept. of Health, who, during a July 22 event hosted by the Brookings Institution, detailed the challenges she faced in trying to get a costly curative therapy to more people while facing down a $2 billion budget deficit.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.